Description
Admit (Sitagliptin) is recommended as a monotherapy, combination medication, or in addition to insulin for individuals with type II diabetes mellitus (non-insulin dependent diabetes mellitus) in order to enhance glycemic control.





₨356.50
Admit (Sitagliptin) is recommended as a monotherapy, combination medication, or in addition to insulin for individuals with type II diabetes mellitus (non-insulin dependent diabetes mellitus) in order to enhance glycemic control.




Reviews
There are no reviews yet.